These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2091733)

  • 1. Biochemical basis for the activity and selectivity of oral antifungal drugs.
    Vanden Bossche H; Marichal P; Gorrens J; Coene MC
    Br J Clin Pract Suppl; 1990 Sep; 71():41-6. PubMed ID: 2091733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Candida drugs--the biochemical basis for their activity.
    Vanden Bossche H; Willemsens G; Marichal P
    Crit Rev Microbiol; 1987; 15(1):57-72. PubMed ID: 3319421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors.
    Vanden Bossche H; Marichal P
    Am J Obstet Gynecol; 1991 Oct; 165(4 Pt 2):1193-9. PubMed ID: 1951574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical approaches to selective antifungal activity. Focus on azole antifungals.
    Vanden Bossche H; Marichal P; Gorrens J; Coene MC; Willemsens G; Bellens D; Roels I; Moereels H; Janssen PA
    Mycoses; 1989; 32 Suppl 1():35-52. PubMed ID: 2561184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.
    Venkateswarlu K; Denning DW; Kelly SL
    J Med Vet Mycol; 1997; 35(1):19-25. PubMed ID: 9061581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to azole antifungals.
    Marichal P; Vanden Bossche H
    Acta Biochim Pol; 1995; 42(4):509-16. PubMed ID: 8852341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
    Cabral ME; Figueroa LI; Fariña JI
    Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.
    Vanden Bossche H; Ausma J; Bohets H; Vermuyten K; Willemsens G; Marichal P; Meerpoel L; Odds F; Borgers M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3272-8. PubMed ID: 15328084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of different inhibitors of sterol biosynthesis on both fungal growth and aflatoxin production.
    Fanelli C; Fabbri AA; Brasini S; De Luca C; Passi S
    Nat Toxins; 1995; 3(2):109-13. PubMed ID: 7613735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents.
    Odds FC; Cheesman SL; Abbott AB
    Sabouraudia; 1985 Dec; 23(6):415-24. PubMed ID: 3913012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifolates as antimycotics? Connection between the folic acid cycle and the ergosterol biosynthesis pathway in Candida albicans.
    Navarro-Martínez MD; Cabezas-Herrera J; Rodríguez-López JN
    Int J Antimicrob Agents; 2006 Dec; 28(6):560-7. PubMed ID: 17046206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terconazole. Pharmacology of a new antimycotic agent.
    Cauwenbergh G; Vanden Bossche H
    J Reprod Med; 1989 Aug; 34(8 Suppl):588-92. PubMed ID: 2677363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
    Meerpoel L; Backx LJ; Van der Veken LJ; Heeres J; Corens D; De Groot A; Odds FC; Van Gerven F; Woestenborghs FA; Van Breda A; Oris M; van Dorsselaer P; Willemsens GH; Vermuyten KJ; Marichal PJ; Vanden Bossche HF; Ausma J; Borgers M
    J Med Chem; 2005 Mar; 48(6):2184-93. PubMed ID: 15771461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and antifungal activity of 1-(1,2,4-triazolyl-1H-1-yl)-2-(2,4-diflurophenyl)-3-(4-substituted benzyl-1-piperazinyl)-2-propanols].
    Sheng CQ; Zhang WN; Ji HT; Song YL; Yang S; Zhou YJ; Zhu J; Lü JG
    Yao Xue Xue Bao; 2003 Sep; 38(9):665-70. PubMed ID: 14730915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ergosterol biosynthesis inhibition: a target for antifungal agents.
    Barrett-Bee K; Dixon G
    Acta Biochim Pol; 1995; 42(4):465-79. PubMed ID: 8852337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
    Rezaei Z; Khabnadideh S; Pakshir K; Hossaini Z; Amiri F; Assadpour E
    Eur J Med Chem; 2009 Jul; 44(7):3064-7. PubMed ID: 18760508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and prospective developments in antifungal drugs.
    Cauwenbergh G
    Acta Derm Venereol Suppl (Stockh); 1986; 121():147-53. PubMed ID: 3012922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Attack point of ergosterol biosynthesis. Drugs and pharmacology].
    Bracher F
    Pharm Unserer Zeit; 2003; 32(2):118-23. PubMed ID: 12677964
    [No Abstract]   [Full Text] [Related]  

  • 19. Antifungal agents: mode of action in yeast cells.
    Carrillo-Muñoz AJ; Giusiano G; Ezkurra PA; Quindós G
    Rev Esp Quimioter; 2006 Jun; 19(2):130-9. PubMed ID: 16964330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel method for studying ergosterol biosynthesis by a cell-free preparation of Aspergillus fumigatus and its inhibition by azole antifungal agents.
    Ballard SA; Ellis SW; Kelly SL; Troke PF
    J Med Vet Mycol; 1990; 28(4):335-44. PubMed ID: 2176688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.